GlassScriptPhysician profile
Noel S Baker
NPI 1386605590
$1,014.14
in general payments reported to CMS, 2019-2025
13 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2021: $16.50 · 2022: $19.10 · 2023: $471 · 2024: $29.84 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399 · Travel and Lodging: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.06 |
| Travel and Lodging | $256.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $649.24 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $100.11 | 2019-2021 | |
| Genzyme Corporation | $44.62 | 2019 | |
| Genentech USA, INC. | $42.44 | 2019 | |
| Alkermes, INC. | $29.84 | 2024 | Vivitrol |
| Ucb, INC. | $25.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.65 | 2019 | |
| Greenwich Biosciences, INC. | $19.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.10 | 2022 | |
| Haemonetics Corporation | $17.72 | 2025 | Teg6s Hemostasis System |
| Bayer Healthcare Pharmaceuticals INC. | $16.03 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.12 | 2019 | |
| Lilly USA, LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.